Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

被引：1
|
作者：
Bordonaro, Roberto
Sobrero, Alberto F.
Frassineti, Luca
Ciuffreda, Libero
Aprile, Giuseppe
Thomas, Anne L.
Moore, Yan
Zilocchi, Chiara
Dochy, Emmanuelle
Taieb, Julien
Ferry, David Raymond
机构：
[1] Garibaldi Hosp Catania, Catania, Italy
[2] IRCCS Osped San Martino IST, Genoa, Italy
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Citta Salute & Sci Torino, Turin, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ Leicester, Leicester, Leics, England
[7] Sanofi Oncol, Cambridge, MA USA
[8] Sanofi, Milan, Italy
[9] Sanofi Oncol, Diegem, Belgium
[10] APHP, Paris, France
[11] Paris Descartes Univ, Paris, France
[12] New Cross Hosp, Wolverhampton, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study
    Satake, Hironaga
    Ando, Koji
    Yasui, Hisateru
    Negoro, Yuji
    Kinjo, Tatsuya
    Yuge, Koutarou
    Baba, Kenji
    Orita, Hiroyuki
    Hirata, Keiji
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
    Ishiguro, Atsushi
    Nakatsumi, Hiroshi
    Harada, Kazuaki
    Yuki, Satoshi
    Sawada, Kentaro
    Sogabe, Susumu
    Ando, Takayuki
    Sasaki, Yusuke
    Yoshikawa, Ayumu
    Nakamura, Michio
    Dazai, Masayoshi
    Tateyama, Miki
    Muto, Osamu
    Kotaka, Masahito
    Sagawa, Tamotsu
    Hatanaka, Kazuteru
    Takagi, Ryo
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 113 - 113
  • [43] Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
    Zhu, J. L.
    Li, S.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Activity of aflibercept (Afli) in combination with FOLFIRI (F) for patients with metastatic colorectal cancer (mCRC) in a real-life setting in Spain: Final results of the retrospective study Named Patient Program.
    Sastre, Javier
    Feliu, Jaime
    Martinez, Purificacion
    Buges, Cristina
    Carlos Mendez, Jose
    Alcaide, Julia
    Garcia, Teresa
    Valladares, Manuel
    Marrupe, David
    Delgado, Ignacio
    Salgado Fernandez, Mercedes
    Martin Valades, Jose Ignacio
    Juarez, Asuncion
    Martin Martinez, Jose Miguel
    Lopez, Ana
    Quintero Aldana, Guillermo Alfonso
    Donnay, Olga
    Vera, Ruth
    del Pozo, Nieves
    de Corcuera Frutos, Isabela Diaz
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Quality of life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) - interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
    von Moos, R.
    Scholten, F.
    Derigs, H. -G.
    Gruenberger, B.
    Thaler, J.
    Hofheinz, R. -D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 55 - 55
  • [46] Quality of life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC): Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ0113)
    von Moos, R.
    Scholten, F.
    Derigs, H-G.
    Gruenberger, B.
    Thaler, J.
    Hofheinz, R. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] INTRAVENOUS (IV) AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH IRINOTECAN/5-FU (FOLFIRI) FOR SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A MULTINATIONAL PHASE III TRIAL (EFC10262-VELOUR).
    Van Cutsem, Eric
    Tabernero, Josep
    Lakomy, Radek
    Prausova, Jana
    Ruff, Paul
    Van Hazel, Guy
    Moiseyenko, Vladimir
    Ferry, David
    McKendrick, Joe
    Tellier, Alexia
    Castan, Remi
    Allegra, Carmen
    ANNALS OF ONCOLOGY, 2011, 22 : v18 - v18
  • [48] Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
    Satake, Hironaga
    Ando, Koji
    Oki, Eiji
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Tsuji, Akihito
    Mori, Masaki
    BMC CANCER, 2020, 20 (01)
  • [49] Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
    Hironaga Satake
    Koji Ando
    Eiji Oki
    Mototsugu Shimokawa
    Akitaka Makiyama
    Hiroshi Saeki
    Akihito Tsuji
    Masaki Mori
    BMC Cancer, 20
  • [50] A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation
    Lenz, Heinz-Josef
    Ahn, Daniel H.
    Ridinger, Maya
    Erlander, Mark G.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345